

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name: NanoDrops Ltd. www.nano-drops.com

CEO name: Daria Lemann-Blumenthal

CATEGORY: Medical Devices

SESSION:

- Illuminating the Path: Innovations and Challenges in Eye Care

The answers below should not exceed 60 words per question:

- **Executive Summary / Investment Rational:** Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date, and management strengths.

NanoDrops is a med-tech company pioneering one-of-a-kind vision correction technology, empowering patients to customize their visual acuity as their vision needs evolve. This pattern-imprinting-nanoparticle technology is a new concept for treating refractive errors, with a global Serviceable Available Market of 581M presbyopes and 646M myopes. Daria Lemann-Blumenthal, CEO, who sold her previous company to Alcon, and Prof. David Smadja, co-founder and CMO, are leading the company, backed by Sanara Capital and by a leading strategic player. NanoDrops has raised \$8.1M to date. It is at a pre-clinical stage, looking to raise \$15M for its first-in-human studies, planned for 2026.

- **Core Technology:** What is technology, its uniqueness, and its value proposition?

NanoDrops' corneal-pattern-imprinting technology is activated by a proprietary nanoparticle filling that diverts the light beams, resulting in a refractive vision correction. Patients can choose between a short-term and a long-lasting solution, based on the type of nanoparticles chosen. Their visual correction can be re-adjusted as needed through a repeatable, minimally invasive and reversible procedure — unique in today's refractive treatment landscape.

- **Product Profile/Pipeline:** Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

The NanoDrops product comprises a laser that micro-imprints a personalized pattern on the cornea, and a procedural kit that includes an optical mask and nanoparticle filling. The first entry point to the market will be for presbyopia to allow patients to be spectacle-free. The company will start first-in-human studies in Israel, Europe, and Australia in 2026.

- **Business Strategy:** Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

The company's recurring revenue business model includes a procedural kit comprising an optical mask and a nanoparticle filling ampule. The procedure will be out-of-pocket and repeatable, offering clinics an expanded treatment portfolio with a high-margin revenue stream. The NanoDrops product will be compatible with existing excimer lasers, a key enabler for rapid market adoption.

What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

NanoDrops is in the pre-clinical phase and planning a First-in-Human clinical trial at the beginning of 2026. The team is comprised of twelve seasoned employees and consultants. We are about to kick off series A financing round to raise \$12M to support our clinical, regulatory, and business development plans.